rs61759167 — PRDM16

PRDM16 and Motion Sickness — A Vestibular-Migraine Overlap Locus

Most people think of motion sickness as a minor inconvenience. Genetics says otherwise. In 2015, the first genome-wide association study of motion sickness — analyzing 80,494 participants¹¹ 80,494 participants
Hromatka et al. Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Human Mol Genet, 2015 — found 35 SNPs reaching genome-wide significance, implicating genes involved in inner ear development, nervous system function, and vestibular signaling. rs61759167 was one of the strongest hits, with a p-value of 4×10⁻¹³. The same T allele was independently associated with antimigraine medication use (a proxy for migraine diagnosis) at P=8×10⁻¹¹ — making this variant one of the clearest demonstrations that motion sickness and migraine share overlapping genetic architecture.

The Mechanism

rs61759167 sits in the first intron of PRDM16²² PRDM16
PR/SET Domain 16 — a zinc-finger transcription factor that acts as a master switch for multiple cell fate decisions, most notably the conversion of progenitor cells into brown/beige adipocytes and, during development, specification of neural crest cells at chromosome 1p36.32. This intronic region likely contains regulatory elements that modulate PRDM16 expression levels in relevant tissue contexts.

The neurovascular connection is plausible from multiple angles. PRDM16 is expressed in the developing inner ear and neural crest-derived structures including those of the peripheral nervous system. The perivascular fat surrounding cranial blood vessels also expresses PRDM16, and loss of PRDM16 function in adipocytes triggers vascular remodeling and increased vascular reactivity — a mechanism directly relevant to migraine, which is fundamentally a neurovascular disorder. The shared signal for both motion sickness and migraine at this locus strongly implies that PRDM16 influences a shared biological substrate: perhaps vestibular sensitivity, perhaps trigeminovascular reactivity, or both.

rs61759167 is located approximately 8 kb from rs2651899, the well-established PRDM16 migraine locus identified in the original Women's Genome Health Study GWAS³³ GWAS
Chasman et al. Genome-wide association study reveals three susceptibility loci for common migraine. Nat Genet, 2011. Whether rs61759167 and rs2651899 are in strong linkage disequilibrium⁴⁴ linkage disequilibrium
LD — the tendency for nearby variants to be inherited together — meaning they may tag the same causal variant, or they may represent independent signals in a complex regulatory region within PRDM16 intron 1 has not been definitively established.

The Evidence

The Hromatka 2015 GWAS⁵⁵ Hromatka 2015 GWAS
Hromatka et al. Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis remains the only large-scale genetic study of motion sickness. At 80,494 participants it is among the largest single-trait GWAS ever conducted at the time of publication, giving strong statistical confidence to the rs61759167 association (P=4×10⁻¹³, far exceeding the 5×10⁻⁸ genome-wide significance threshold). The study confirmed that motion sickness shares genetic architecture with migraines, postoperative nausea, vertigo, and altitude sickness, and noted sex-specific effects with women experiencing up to three times stronger genetic effects than men.

The PRDM16 migraine association at the neighboring rs2651899 locus is independently replicated across populations. A meta-analysis by Lee et al. 2020⁶⁶ meta-analysis by Lee et al. 2020
Lee et al. Association of rs2651899 Polymorphism in PRDM16 and Common Migraine Subtypes. Headache, 2020 of six studies (2,853 cases, 9,319 controls) confirmed OR = 1.42 for migraine under a recessive model. These findings at the adjacent variant strengthen the biological case for PRDM16 intron 1 as a genuine migraine susceptibility region.

For magnesium as an intervention: a systematic review by von Luckner and Riederer 2018⁷⁷ systematic review by von Luckner and Riederer 2018
von Luckner, Riederer. Magnesium in Migraine Prophylaxis — Is There an Evidence-Based Rationale? Headache, 2018 analysed five randomised double-blind placebo-controlled trials and concluded that high-dose magnesium dicitrate 600 mg/day is Grade C (possibly effective) for migraine prevention, with one high-quality trial showing significant attack reduction.

Practical Actions

Carriers of the T allele — and especially TT homozygotes — face a dual vulnerability: heightened motion sickness susceptibility and elevated migraine risk. The practical implications are distinct:

For motion sickness, the genetic signal offers predictive utility. T carriers should plan seating strategies proactively (front seat in cars, forward-facing seats on trains, above-wing seats on aircraft, above-deck positions on boats) and consider first-line motion sickness interventions before exposure rather than reactively.

For migraine prevention, magnesium supplementation (400–600 mg/day as glycinate or dicitrate) has direct mechanistic rationale: magnesium deficiency lowers the threshold for cortical spreading depression (the electrophysiological event underlying migraine aura and believed to trigger the pain cascade), and serum/brain magnesium is consistently low during migraine attacks. Clinicians experienced in headache medicine often prescribe oral magnesium as first-line preventive therapy given its safety profile.

Carriers who develop both motion sickness and migraines — a co-occurrence this variant predicts — should be evaluated for vestibular migraine⁸⁸ vestibular migraine
a variant of migraine in which vestibular symptoms (dizziness, vertigo, imbalance) are the dominant feature rather than or in addition to headache; underdiagnosed and often misclassified as Ménière's disease, which is specifically linked to motion sensitivity and is treatable with standard migraine preventives.

Interactions

The nearest PRDM16 variant in the database, rs2651899, covers overlapping migraine biology from the same gene region. rs10166942 (TRPM8), another SNP from the Chasman 2011 migraine GWAS, represents an independent pathway (cold-sensing ion channel) that converges on similar neurovascular vulnerability. Carrying risk alleles at multiple migraine-associated loci (rs61759167, rs2651899, rs10166942) is expected to compound migraine susceptibility, though formal interaction studies for this specific combination have not been published.